Randomised, Controlled, Open-Labelled, Multi-Centre Comparison of Thalidomide Versus High-Dose Dexamethasone for the Treatment of Relapsed and/or Refractory Multiple Myeloma.
Phase of Trial: Phase III
Latest Information Update: 23 Feb 2017
At a glance
- Drugs Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMUM
- Sponsors Celgene Corporation; Pharmion Corporation
- 01 Dec 2011 Primary endpoint 'Time-to-disease-progression' has not been met.
- 29 Sep 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History